S-1: Reliance Global Group Files for Resale of Up to 16.1M Shares

Sentiment:

Resale Registration Statement 27 August 2026 5:16 PM

📋All filings for Reliance Global Group, INC

Reliance Global Group, Inc. has filed an S-1 registration statement to allow White Lion Capital, LLC to resell up to 16,107,568 shares of common stock, potentially raising up to $48.4 million for the company.

Capital raiseThe filing relates to the potential resale of up to 16,107,568 shares of common stock by White Lion Capital, LLC, which may result in the Company receiving up to approximately $48.4 million in aggregate gross proceeds from White Lion under the White Lion Purchase Agreement.This is part of an equity line of credit (ELOC) with an aggregate commitment of $50.0 million, of which approximately $1.6 million had been sold as of the filing date.The proceeds are intended for working capital, operations, growth, debt payments, capital investments, and general corporate purposes.

Worse than expectedThe filing details a significant potential dilution of up to 959% of outstanding shares due to the resale of shares by White Lion Capital.The purchase price for shares sold to White Lion is based on a discount to the market price, potentially magnifying the dilutive effect.The company has a history of non-compliance with Nasdaq listing rules, and while it has regained compliance for the bid price, it faces ongoing challenges with the Market Value of Listed Securities.The company's reliance on an equity line of credit and the potential for future registration statements to be delayed or ineffective highlight financial uncertainties.

Summary

Reliance Global Group, Inc. (the Company) has filed a Form S-1 registration statement to permit White Lion Capital, LLC (White Lion) to resell up to 16,107,568 shares of its common stock.
These shares may be issued to White Lion under an equity line of credit (ELOC) established by a Common Stock Purchase Agreement, as amended, which has an aggregate commitment of $50.0 million.
As of the filing date, approximately $1.6 million of shares had been sold under the ELOC, with approximately $48.4 million remaining available.
The Company is not selling any securities in this offering and will not receive proceeds from White Lion's resales; proceeds are generated only when the Company sells shares to White Lion.
The filing also details the Company's business operations, focusing on insurance brokerage, Insurtech platforms (5MinuteInsure.com and RELI Exchange), and strategic initiatives in AI, technology, and healthcare.
Recent developments include a reverse stock split (1-for-40) to regain Nasdaq compliance, officer appointments, and related-party transactions concerning investments in LifeSci Global Group LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant dilution risk, potential for stock price decline, and the company's ongoing struggles with Nasdaq listing requirements.

Positives

The company has an established equity line of credit with White Lion Capital, providing potential access to up to $50 million in capital.
The company has regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
The company has launched Insurtech platforms (5MinuteInsure.com and RELI Exchange) aimed at modernizing insurance distribution and operations.
Strategic initiatives include expansion into AI, technology, and healthcare sectors, diversifying beyond core insurance operations.

Negatives

The resale of up to 16,107,568 shares by White Lion represents a significant potential dilution to existing shareholders, constituting approximately 959% of outstanding shares as of August 26, 2026.
Sales under the ELOC are at a discount to market price (potentially 90% of the lowest traded price), magnifying the dilutive effect.
The company has a history of struggling with Nasdaq listing requirements, including the minimum bid price and market value of listed securities, with a warning about future compliance.
The company may need to file additional registration statements if market prices decline, potentially delaying access to capital.
The company has broad discretion in using proceeds from any sales to White Lion, which may not align with investor expectations.
The company has not historically paid cash dividends and does not intend to in the foreseeable future, prioritizing reinvestment in business growth.

Risks

Significant dilution to existing stockholders due to the potential resale of a large number of shares by White Lion Capital.
Downward pressure on the stock price and increased volatility resulting from actual or anticipated resales by White Lion.
Potential delisting from Nasdaq if the company fails to maintain continued listing requirements, such as the minimum Market Value of Listed Securities ($5.0 million).
The company's ability to access the full ELOC commitment is subject to various conditions, including the effectiveness of registration statements and trading halts.
The company's reliance on an aggressive acquisition strategy carries inherent integration and financial risks.
The speculative nature of investments in the technology and life sciences sectors, including minority investments.
Risks associated with cybersecurity incidents, system failures, and legal proceedings.
The company's need to raise additional capital, which may not be available on acceptable terms or at all.

Future Outlook

The company may receive up to approximately $48.4 million in aggregate gross proceeds from White Lion under the White Lion Purchase Agreement in connection with future sales of its common stock. Proceeds will be used for working capital, operations, growth, debt payments, capital investments, and general corporate purposes. Management retains broad discretion over the allocation of these proceeds.

Management Comments

The Company's primary strategy is to identify specific risk to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows.
We intend to continue investing in the development and deployment of AI technologies that complement our insurance operations, improve scalability and create potential future commercialization opportunities.
We expect to continue evaluating strategic opportunities across our insurance, artificial intelligence, technology and healthcare businesses.

Industry Context

StockSavvy.ai notes that Reliance Global Group is operating in the competitive insurance brokerage sector, attempting to leverage Insurtech and AI to gain an edge. The company's aggressive acquisition strategy and diversification into technology and healthcare are common themes among growth-oriented firms, but also introduce significant execution and integration risks.

Comparison to Industry Standards

The company's Insurtech platforms, 5MinuteInsure.com and RELI Exchange, aim to streamline insurance quoting and purchasing, a trend seen across the industry where digital transformation is key.
The use of AI for automating back-office workflows is becoming increasingly standard in financial services and insurance to improve efficiency and reduce costs.
The company's strategy of acquiring undervalued insurance agencies aligns with consolidation trends in the fragmented insurance brokerage market.
However, specific performance metrics or comparisons against industry benchmarks for these initiatives are not detailed in this filing.

Management Changes

Role	New Person	Effective Date	Reason
Chief Operating Officer	Judah Korman	2026-06-18	Appointment
Chief Technology Officer	Zack Wilder	2026-06-18	Appointment
Vice President	Mordy Beyman	2026-06-18	Appointment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stockholder Approval for Nasdaq Rule 5635(d)	Stockholders approved issuances under the White Lion Purchase Agreement in excess of the 19.99% Exchange Cap.	2026-05-06	Increases potential dilution to stockholders by allowing for larger issuances under the ELOC.
Board of Directors Composition	Re-election of existing directors at the 2026 Annual Meeting.	2026-05-06	Maintains continuity in board leadership.
Independent Directors	Reconstitution of audit, compensation, and nominating committees to consist solely of independent directors for LGG transactions.	2026-04-29	Enhances corporate governance and oversight for related-party transactions.

Legal Proceedings

The filing mentions 'risks associated with legal proceedings and compliance obligations' generally, but no specific current litigation is detailed in this S-1.

Related Party Transactions

Investment in LifeSci Global Group LLC (LGG): The Company holds 51% of LGG, with the remaining 49% held by LifeSci Management Group LLC (owned by CEO Ezra Beyman, Director Scott Korman, and David Turner). This constitutes a related-party transaction.
Promissory Note: EZRA International Group LLC (a subsidiary) issued a Promissory Note for up to $2,000,000 to LGG.
Unit Subscription Agreement: LGG agreed to subscribe for up to $2,000,002 in Class A units of Innervate Radiopharmaceuticals LLC.
Officer Appointments: Judah Korman (son of Director Scott Korman) appointed COO; Mordy Beyman (son of CEO Ezra Beyman) appointed VP. These are related-party appointments.

Stakeholder Impact

Shareholders: Significant dilution risk from potential resale of shares by White Lion Capital; potential for stock price decline and increased volatility; potential impact on voting power if preferred stock is issued.
Creditors: Use of proceeds for debt payments may benefit creditors, but overall financial health and ability to raise capital impact debt servicing.
Employees: Appointment of new officers and potential equity awards under incentive plans could impact employee morale and retention.
Management: Appointments of sons of existing director and CEO raise potential governance concerns, though steps were taken to ensure independent approval of related-party transactions.

Next Steps

White Lion Capital, LLC may sell shares of common stock from time to time under this prospectus.
The Company will continue to evaluate strategic opportunities across its insurance, AI, technology, and healthcare businesses.
The Company must ensure the registration statement remains effective for the resale of shares by White Lion.

Key Dates

Date	Description
2013-08-02	Company incorporated in Florida under the name Ethos Media Network, Inc.
2018-10-18	Company renamed Reliance Global Group, Inc.
2025-08-26	Common Stock Purchase Agreement entered into with White Lion Capital, LLC.
2025-09-04	Prior Registration Statement on Form S-1 (File No. 333-289900) declared effective by the SEC.
2025-11-05	Amendment No. 1 to the White Lion Purchase Agreement entered into.
2026-03-12	Amendment No. 2 to the White Lion Purchase Agreement entered into, increasing commitment to $50.0 million.
2026-05-06	2026 Annual Meeting of Stockholders held; stockholders approved issuances under White Lion Purchase Agreement in excess of the Exchange Cap.
2026-05-15	1-for-40 reverse stock split (Reverse Split-2026) became effective.
2026-08-27	Date of filing of the S-1 Registration Statement.

Recommendation

hold

The filing presents a mixed picture. While the ELOC offers potential capital, the significant dilution risk and ongoing Nasdaq listing challenges are substantial concerns. The company's strategic diversification and Insurtech initiatives show promise, but the immediate impact of share dilution and the uncertainty surrounding Nasdaq compliance warrant a cautious 'hold' stance until the company demonstrates sustained operational improvement and stable listing status.

Keywords

Reliance Global Group, S-1 Filing, Equity Line of Credit, White Lion Capital, Common Stock, Resale Registration, Insurtech, Nasdaq Listing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.